This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Lou Basenese Biography and Net Worth

Director of ENDRA Life Sciences

Lou Basenese joined ENDRA's board of directors in 2020. Basenese, 42, is the Founder and Chief Analyst of Disruptive Tech Research, LLC, an independent equity research and advisory firm focused exclusively on disruptive technology companies that has served the investment management community since June 2014. Since 2005, Basenese has also managed The Basenese Group, LLC, a consulting business focused on communications and business development for private and public small and microcap businesses. Mr. Basenese holds an M.B.A. in Finance from the Crummer Graduate School of Business at Rollins College and a Bachelor of Arts from the University of Florida. He is also a former Series 7 and Series 66 license holder.

How do I contact Lou Basenese?: The corporate mailing address for Mr. Basenese and other ENDRA Life Sciences executives is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. ENDRA Life Sciences can also be reached via phone at (734) 335-0468 and via email at [email protected]. Learn More on Lou Basenese's contact information.
Has Lou Basenese been buying or selling shares of ENDRA Life Sciences?: Lou Basenese has not been actively trading shares of ENDRA Life Sciences in the last ninety days. Most recently, Lou Basenese sold 45,000 shares of the business's stock in a transaction on Wednesday, August 25th. The shares were sold at an average price of $1.83, for a transaction totalling $82,350.00. Learn More on Lou Basenese's trading history.
Who are ENDRA Life Sciences' active insiders?: ENDRA Life Sciences' insider roster includes Lou Basenese (Director), and Michael Thornton (CTO). Learn More on ENDRA Life Sciences' active insiders.
Are insiders buying or selling shares of ENDRA Life Sciences?: In the last year, ENDRA Life Sciences insiders bought shares 2 times. They purchased a total of 98,333 shares worth more than $124,749.60. The most recent insider tranaction occured on May, 18th when CTO Michael Milos Thornton bought 15,000 shares worth more than $24,750.00. Insiders at ENDRA Life Sciences own 4.8% of the company. Learn More about insider trades at ENDRA Life Sciences.
Information on this page was last updated on 5/18/2023.

Lou Basenese Insider Trading History at ENDRA Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/25/2021	Sell	45,000	$1.83	$82,350.00
5/28/2020	Buy	10,000	$0.89	$8,900.00
5/26/2020	Buy	10,000	$0.84	$8,400.00
5/21/2020	Buy	10,000	$0.71	$7,100.00

Lou Basenese Buying and Selling Activity at ENDRA Life Sciences

ENDRA Life Sciences Company Overview

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Today's Range

Now: $0.26

$0.25

$0.26

50 Day Range

MA: $0.80

$0.23

$1.21

2 Week Range

Now: $0.26

$0.22

$2.79

Volume

21,711 shs

Average Volume

164,331 shs

Market Capitalization

$2.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98